The primary cause of anemia in CKD is the reduced production of erythropoietin (EPO) (2, 3), however, approximately 5–43% of patients exhibit hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) despite adequate dosing (4, 5). This evidence concerns the gene EPO and chronic kidney disease.